Lung Health Study II
Launched by UNIVERSITY OF MINNESOTA · Oct 27, 1999
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States and a major cause of morbidity, is a spectrum of chronic lung diseases including clinical diagnoses of chronic bronchitis, emphysema, and combinations of both. Varying degrees of bronchoreactivity occur over the entire spectrum. Asthma and COPD have many features in common. Distinction is usually dependent on clinical features and clinical course. The diagnosis of asthma will not exclude a patient from the designation of COPD for this study, although criteria for exclusion inclu...
Gender
ALL
Eligibility criteria
- Inclusion:
- • 1. Previously participated in or screened for the Lung Health Study I
- • 2. Ages 40 to 69
- • 3. Forced expiratory volume at one second (FEV1)/forced vital capacity(FVC) \< 70 percent
- • 4. Forced expiratory volume at one second (FEV1) 30 to 90 percent predicted.
- Exclusions:
- • 1. Cancer
- • 2. Recent myocardial infarction
- • 3. Alcoholism
- • 4. Heart Failure
- • 5. Insulin-dependent diabetes mellitus
- • 6. Neuropsychiatric disorders
- • 7. Used bronchodilators or oral or inhaled corticosteroids in previous year
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
John Connett
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials